Key result
Tissue plasminogen activator (t-PA) provides prompt reperfusion and restoration of coronary artery patency in acute myocardial infarction, with minor bleeding as the most significant adverse effect.
Why the study?
Does recombinant tissue plasminogen activator (t-PA) improve reperfusion and clinical outcomes in patients with acute myocardial infarction?
Population
Patients with acute myocardial infarction (evolving MI)
Design
Review
Authors
Loading...
May support t-PA reperfusion in AMI; Level 5 evidence leaves open need for confirmatory RCTs.
Does recombinant tissue plasminogen activator (t-PA) improve reperfusion and clinical outcomes in patients with acute myocardial infarction?
Recombinant t-PA is an effective, clot-selective thrombolytic agent that achieves rapid reperfusion in acute myocardial infarction with a relatively safe adverse effect profile.
Rogers et al. (1987) conducted a review in Acute Myocardial Infarction. Tissue Plasminogen Activator (t-PA) was evaluated. Tissue plasminogen activator (t-PA) provides prompt reperfusion and restoration of coronary artery patency in acute myocardial infarction, with minor bleeding as the most significant adverse effect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: